Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

July 31, 2024

Study Completion Date

December 31, 2024

Conditions

Advanced Solid Tumor

Interventions

BIOLOGICAL

Nemvaleukin alfa

IV infusion over 30 minutes

BIOLOGICAL

Pembrolizumab

IV infusion over 30 minutes

Trial Locations (6)

NEXT Virginia, Fairfax

Hospital Clinico San Carlos, Madrid

CIOCC HM Sanchinarro, Madrid

START Midwest, Grand Rapids

MD Anderson Cancer Center, Houston

START Mountain, West Valley City